… asymptomatic CMV infection and consecutive fetal CMV infection confirmed by high CMV
VL in AF. Serologic findings in the first trimester hinted at a primary CMV infection. The first …

… Treatment of CMV infection has been difficult in the past, requiring intravenous treatment
with … The development of ganciclovir's prodrug, valganciclovir, with 10-fold greater oral …

… for congenital CMV infections. Currently, two different antivirals are in use: oral valganciclovir
(VGC) and … The aim of our study was to analyze the available data on the VGC treatment of …

… cytomegalovirus infection at our hospital during the study period, 36 patients (47%) received
antiviral treatment. Of … Since one patient who had completed treatment with VGCV before …

… In conclusion, 450 mg of valganciclovir was effective in preventing CMV infection in kidney
transplant patients compared with the standard dose and showed the best rank probability. In …

… In the case of symptomatic cCMV, we actually recommend treatment with oral valganciclovir
… Valganciclovir is reserved for congenitally-infected neonates with the symptomatic disease …

… In conclusion, the valacyclovir treatment significantly increased the portion of asymptomatic
neonates from 43%, without treatment, to 82% with treatment. There was no overlap in 95% …

… valacyclovir given in pregnancy is effective for improving the outcome of moderately
symptomatic infected … of an antiviral drug to treat cytomegalovirus-infected fetuses. Moreover, this …

… and valganciclovir) serves as the first-line drug for CMV prevention and therapy, while
foscarnet and cidofovir are reserved for the management of refractory and resistant CMV infection. …

… Second, the treatment of congenital CMV infections with valganciclovir has beneficially
improved both hearing and neurologic outcomes, both fundamental advances for these children. …